Aspergilloma

Last updated
Aspergilloma
Other namesMycetoma, fungus ball, moldy lungs
Aspergillomas complicating tuberculosis.jpg
Aspergillomas complicating tuberculosis: multiple aspergillomas within large cavitary lesions of tuberculous origin.
Specialty Infectious disease
Causes Aspergillus fungal infection
Diagnostic method Chest x-ray show tumour like opacity. Serology can be helpful. Fungal hyphae seen on KoH mount and sputum culture grows fungus
Frequency
  • Patients with CPA: 25%
  • Global 5-year period prevalence: 18 in 100,000

A pulmonary aspergilloma, also known as chronic pulmonary aspergillosis, is a human infectious disease of the lung caused by the colonization of a cavity by a fungus of the genus Aspergillus , most commonly Aspergillus fumigatus . The spores are transmitted through the air and are not contagious between individuals. It is a frequent complication of tuberculous cavities, which are themselves the primary sequelae of pulmonary tuberculosis, and correspond to localized lung tissue destruction. The cavities of pulmonary tubercles are poorly equipped to defend against Aspergillus infection, allowing the fungus to proliferate and form a pseudo-tumor that partially fills the cavity. It is estimated that more than 370,000 people worldwide develop an aspergilloma each year.

Contents

Several forms of aspergilloma exist, with varying severity and symptoms depending on the patient's overall health. Aspergillomas are distinguished from other Aspergillus infections by their localized nature. They are categorized based on their size and the degree of underlying lung destruction. The primary complication is bleeding, which leads to expectoration of blood, sometimes life-threatening. Diagnosis is based on a combination of radiological findings and fungal identification. Treatment is either medical, using antifungals, or surgical.

History

The genus Aspergillus was first described in 1729 by Italian botanist Pier Antonio Micheli. [1] The first description of a human aspergilloma is attributed to John Hughes Bennett in 1842, [2] though this attribution has been questioned. [3] In 1847, Theodor Sluyter reported the first confirmed case of diffuse human aspergillosis, [4] and in 1855, German physician Friedrich Küchenmeister provided the first autopsy description of an aspergilloma developed in an excavated bronchial carcinoma. [5] Aspergillomas in tuberculous cavities were first described in 1856. [6] [7] Their radiological description was not established until 1938, [8] and lesion classification was refined in 1952. [3] The first antifungal treatment trials began in 1959, [9] and surgical treatment was developed in the same decade. [10]

Overview

Causative organisms

Aspergillus fumigatus under electron microscopy. Aspergillus.gif
Aspergillus fumigatus under electron microscopy.

Aspergillus fumigatus is a saprophytic soil fungus, highly prevalent, and one of the most prolific spore producers in the air. Its spores, measuring 2–3 µm in diameter, are small enough to reach the pulmonary alveoli and numerous enough that humans inhale several hundred daily. These spores are typically cleared by the immune system and only become pathogenic under certain conditions. [11]

While all fungi in the Aspergillus genus are potentially pathogenic (e.g., Aspergillus flavus , Aspergillus terreus , Aspergillus niger , and Aspergillus nidulans ), Aspergillus fumigatus accounts for 90% of human pulmonary infections. [11] These infections are categorized into several types: allergic bronchopulmonary aspergillosis, invasive aspergillosis, and aspergilloma. Unlike diffuse infections such as invasive aspergillosis and allergic bronchopulmonary aspergillosis, aspergillomas are localized infections characterized by fungal growth within a cavity. Aspergillus sinusitis is another form, where the fungus develops in a natural sinus cavity of the face. [12]

Predisposing conditions

While diffuse Aspergillus infections typically affect immunocompromised patients, [11] colonization of a pulmonary cavity leading to aspergilloma formation primarily occurs in immunocompetent individuals with underlying chronic lung disease. [11] Aspergillomas are not contagious between humans, as transmission occurs via inhaled air. [13]

Aspergillomas predominantly develop in tuberculous cavities; [14] between 17% and 25% of patients with such cavities also have an aspergilloma. [14] [15] Since the 1980s, this proportion has decreased in Europe. In 2010, 15% of UK patients with aspergilloma had a history of pulmonary tuberculosis, compared to 93% in Korea. [16] Other, less common mycobacterial infections also predispose to aspergillomas. [13]

While the frequency of tuberculous cavities has decreased in developed countries by the late 20th century due to improved management of pulmonary tuberculosis, some tuberculosis patients remain at high risk. [14] [17] Globally, tuberculosis remains the primary risk factor for aspergillomas in the early 21st century, particularly in cases of global immune deficiency or lung destruction. [13] Aspergillomas are the main sequelae of pulmonary tuberculosis: in 2007, 7.7 million people worldwide had pulmonary tuberculosis, with an estimated 372,000 developing at least one aspergilloma, primarily in Southeast Asia, the Pacific, and Africa. [18] Aspergillomas in these patients are often underdiagnosed, mistaken for non-bacillary pulmonary tuberculosis or pulmonary fibrosis. [18] Any tuberculosis patient with hemoptysis should be considered to have an aspergilloma. [17]

Beyond tuberculosis, other lung diseases can lead to cavity formation where aspergillomas may develop. In HIV-positive patients, pneumocystosis is the second most significant risk factor after tuberculosis. [19] In immunocompetent patients, chronic obstructive pulmonary disease, emphysema, and bronchial dilation are the main risk factors apart from tuberculosis. [16] Pulmonary sarcoidosis, though rare, [20] is complicated by aspergilloma in about 6% of cases. [21] Major thoracic surgeries (lobectomy, pneumonectomy, or parietectomy with lung resection) also increase risk. [14] [22] Approximately 3.6% of patients undergoing lobectomy for lung cancer develop an aspergilloma months or years later. [22]

Pathophysiology

Formation of tuberculous cavities

Illustration of a tuberculous cavity communicating with a bronchus. Plate IX Illustrations of pulmonary consumption Wellcome L0074277.jpg
Illustration of a tuberculous cavity communicating with a bronchus.

A cavity is a hollow space within the lung parenchyma. [23] Cavities are a common complication of pulmonary tuberculosis, appearing after primary infection. [24]

Tuberculous bacilli initially form nodules called granulomas, which are surrounded by lymphocytes and macrophages to contain the infection. [24] Granulomas may resolve without scarring or progress to cavities, though the underlying mechanisms are not fully understood. [23] The remnants of destroyed macrophages form the bulk of caseous necrosis at the granuloma's center. [23] In some patients, this necrosis liquefies, creating an environment conducive to bacilli proliferation. Proteolytic enzymes erode the fibrous capsule surrounding the granuloma, and the liquid center may drain, replaced by air from the bronchi. [23] When a tuberculous cavity communicates with the bronchial tree, bacilli dissemination in exhaled air increases contagiousness. [24] [25] The high bacilli load in cavities also promotes resistance to anti-tuberculous drugs. [25] Once the liquefied necrosis is cleared, the granuloma's periphery persists around an empty, infection-prone cavity.

Composition of an aspergilloma

Aspergilloma showing the typical brownish appearance within a well-defined cavity. Aspergilloma complicating tuberculosis (5390415129).jpg
Aspergilloma showing the typical brownish appearance within a well-defined cavity.

An aspergilloma appears as a spherical pseudo-tumor, often termed an "aspergillar ball" [26] or "aspergillar truffle". [27] It consists of fungal filaments (mycelium and hyphae) embedded in a proteinaceous polysaccharide matrix. [28] Sporulating structures line the aspergilloma. [11] [14]

Several clinical forms of chronic pulmonary aspergillosis exist, which may overlap: [29]

Simple aspergillomas are usually solitary, though multiple or bilateral forms exist. [14] In immunocompromised patients, aspergillomas develop throughout the lung, while in immunocompetent individuals, they are more often found at the apex of the upper lobes or the apical segment of the lower lobes. [14] There is a continuum of progression between aspergilloma types. [30] [31] Progression is favored by immunosuppression, [31] particularly uncontrolled HIV infection. [32]

Mechanism of aspergilloma formation

The mechanisms underlying aspergilloma formation are poorly understood [33] and remain debated. [34]

Spore adhesion to the respiratory epithelium, forming a biofilm, is the first step [35] [36] . Spores in contact with bronchial epithelium and alveoli produce enzymes, particularly proteases, that degrade nearby tissue proteins, especially elastin and collagen. [33] [37] Contact with spores causes epithelial desquamation and the release of pro-inflammatory cytokines. [33] Locally produced interleukins contribute to aspergilloma formation, with certain genetic variations promoting complex aspergillomas, [38] alongside the host's genetic immune profile. [39] [34] The resulting desquamation and inflammation reduce the epithelial barrier's effectiveness, facilitating Aspergillus infection. [33]

Clinical manifestations

Aspergillomas are often asymptomatic, [11] [31] discovered incidentally on a chest X-ray or computed tomography performed for other reasons.

Hemoptysis (pulmonary or bronchial bleeding manifesting as bloody sputum) is the most common clinical sign. [11] [40] It affects 54–87% of patients and is massive in 10% of cases. [14] The mechanism triggering bronchial vessel erosion is poorly understood; [14] it may be mechanical, due to the aspergillar mass rubbing against the cavity wall, or chemical, due to local toxin production. Some suggest that anastomoses between bronchial and pulmonary vessels may contribute. [41] The risk of hemoptysis becomes significant when the cavity exceeds 2 cm in diameter. [42]

Another common symptom is a productive wet cough. [13] [40] Other symptoms (fatigue, chronic dry cough, weight loss, fever) are non-specific [31] and may relate to the underlying lung disease, making it difficult to attribute them solely to the aspergilloma.

The annual mortality rate for aspergilloma patients is 5–6%. [31] Up to 26% of patients die from massive hemoptysis. [30]

Diagnostic investigations

Mycological diagnosis

Pathogen identification

Identifying the specific Aspergillus strain can be achieved through various methods. Testing sputum samples is often uninformative due to the high abundance of spores in the air, which can contaminate samples. [43] Sputum analysis should include at least three separate samples to increase the likelihood of identifying the pathogen. [44] Identification via bronchial fibroscopy is far more specific; direct examination looks for mycelial filaments, and culture seeks the strain itself. Cultures are grown on Sabouraud agar with antibiotics or malt extract agar incubated at 30°C. [45]

Molecular detection via PCR is more sensitive than culture and requires only one sample. [44] Biopsy of lesions, typically surgical or via EBUS, offers the highest sensitivity and specificity for mycological diagnosis but is more invasive. [46]

Galactomannan, a complex sugar produced by the fungus, can be detected in sputum. [47] Its antigen may also be detectable in blood. [45]

Immunologically, the A. fumigatus antigen can be sought in sputum. The presence of anti-Aspergillus antibodies in blood, detected via serology, is critical for diagnosis. [43] [40] Serology distinguishes recent from past infections and differentiates simple bronchial colonization from true infection. [48] A negative serology can rule out an aspergilloma in doubtful cases.

Antifungal resistance

Once the strain is identified in culture, testing its sensitivity to antifungals is recommended. [44] Multiple strains with differing sensitivities may coexist in a single patient. [28]

The emergence of Aspergillus resistance to antifungals began in the late 1990s; [49] the first reported case was in 1997. [50] In the Netherlands, resistance rates rose from 2.5% in 2000 to 4.9% in 2002, 6.6% in 2004, and 10% by 2009. [51] Resistance is geographically heterogeneous, primarily affecting Western Europe and Scandinavia. [49] It mainly involves triazoles, [52] the first-line recommended antifungal class.

Initially, resistance developed during treatment. [52] Since 2008, resistance in patients never treated with antifungals has been reported, [53] indicating resistance spread in wild Aspergillus fumigatus populations. [54] Resistance is primarily linked to mutations in the target protein of triazoles, the lanosterol 14α-demethylase enzyme, encoded by the cyp51A gene. [52] Resistant strains are typically resistant to multiple triazoles. [52] Since 2010, other resistance mechanisms have emerged. [54]

Antifungal resistance is concerning due to the limited availability of antifungals, reducing treatment options, particularly as triazoles are the only oral antifungals. However, the risk of global resistance spread is low. [55]

Imaging

On chest X-ray, a simple aspergilloma appears as a dense nodule, often surrounded by an air crescent. [11] X-ray alone is insufficient for diagnosis; a CT scan is recommended. On thoracic CT, the cavity's center is occupied by the aspergilloma. [56] The pseudo-tumor shifts within the cavity with patient movement (Monod sign). [56] In simple aspergillomas, there is no progression between exams, and the cavity wall is typically thin. [13] Complex aspergillomas show thick-walled cavities (or multiple cavities) containing an aspergillar truffle, sometimes with early pulmonary fibrosis. [57] The adjacent pleura may appear fibrosed, with slow but progressive radiological worsening. A ground-glass halo may surround the lesions. [44] [13]

CT imaging appearance

Radiological diagnosis alone is inadequate, as other lesions (e.g., excavated lung cancer, [14] [58] lung abscess, or hydatid cyst [14] ) may appear similar. Injection of iodinated contrast to visualize vessels can detect a Rasmussen aneurysm, [59] a pseudo-aneurysmal dilation of the pulmonary artery near a cavity, at risk of rupture causing massive, often fatal hemoptysis. [60]

PET scans are not useful for aspergilloma diagnosis, [61] as they consistently show hyperfixation and are a differential diagnosis for excavated lung cancers. [62]

Diagnostic approach

Aspergilloma diagnosis relies on a combination of findings: consistency between CT imaging and mycological diagnosis after ruling out other possibilities. If radiological findings are typical, serology alone confirms the diagnosis in over 90% of cases. If serology is negative, fungal presence must be confirmed by other means (culture or PCR): sputum analysis, bronchoalveolar lavage, or biopsy. Other infectious diseases, such as histoplasmosis, coccidioidomycosis, and active pulmonary tuberculosis, must be excluded. Concurrent bacterial infections (e.g., Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Pseudomonas aeruginosa , or anaerobes) do not rule out aspergilloma.

As a localized infection, aspergillomas do not trigger a systemic immune response, so there is no inflammatory syndrome or elevated white blood cell count. [63]

Treatment

Various medical societies have issued guidelines on management, [44] [30] though consensus is not always clear. Managing aspergillomas is complex due to patients’ compromised health, particularly pre-existing respiratory insufficiency from tuberculosis or chronic bronchitis. Treatment is multidisciplinary, involving infectious disease specialists, thoracic surgeons, and pulmonologists. [13]

Antifungal treatment

Itraconazole, a member of the triazole class, is recommended as the first-line treatment. [64] In cases of intolerance, treatment failure, or fungal resistance, voriconazole (also a triazole) [65] or posaconazole may be considered as alternatives. [15] Special attention must be paid to drug interactions caused by triazoles, which affect the activity of other medications due to their role as enzyme inhibitors. [66]

Oral administration of triazoles stabilizes lesions and reduces the risk of massive hemoptysis, typically with minimal side effects. [64] [67] The response to treatment is slow, requiring 4 to 6 months of therapy, or even 9 months in some cases. [15] In patients who respond well to treatment after this duration but are not eligible for surgery, treatment may be extended for several months [67] or even years. [64] Patients whose condition is only stabilized may benefit from long-term treatment, as discontinuation can sometimes lead to worsening symptoms. [64]

Intravenous treatment is typically reserved for patients with rapidly progressing forms or in cases of triazole failure (due to resistance or poor tolerance). Amphotericin B, [68] micafungin, [69] and caspofungin, [70] which are alternatives to triazoles, are only available via injection. An intravenous induction phase followed by oral triazoles is also an option. Even short-term treatment with amphotericin B requires close monitoring of renal function.

If initial antifungal treatment fails, other progressive diseases, particularly a recurrence of tuberculosis, should be investigated. [34] Since antituberculous treatments can induce resistance to azoles, this possibility must also be ruled out. [34]

The use of antifungal therapy alongside surgical intervention is debated. [71] There appears to be no survival benefit or reduction in recurrence rates. [71] [72] [73] However, postoperative antifungal treatment is recommended for immunocompromised patients [71] and those with incomplete surgical resection. No specific treatment duration is recommended; it should be determined on a case-by-case basis. Some experts suggest a minimum total treatment duration of six months.

Surgical indications

Surgery is one of the curative treatments for aspergilloma. [74] [75] [76] It aims to remove all aspergilloma lesions and can range from simple segmental resection (for simple aspergillomas) to lobectomy or pneumonectomy for complex aspergillomas. [77]

For simple aspergillomas, surgery is recommended as the first-line treatment due to low complication rates and the potential for cure. [78] When pulmonary function permits, surgery is the standard treatment. [79] However, some experts suggest that asymptomatic simple aspergillomas should be monitored without antifungal or surgical intervention. For complex aspergillomas, surgical management is primarily indicated in cases of hemoptysis, [74] with lifelong antifungal therapy preferred whenever possible. Surgical procedures for complex aspergillomas are challenging and risky, [75] [76] with recurrence rates reaching up to 25%. [79] Success, defined as the absence of recurrence, depends on complete resection without opening the aspergilloma, which could seed the cavity, and the lung's ability to fully reoccupy the pleural cavity without residual detachment. [80]

Major pulmonary resections, particularly pneumonectomies, have higher complication rates for infectious causes compared to cancer. [81] Complication rates for pulmonary resections for aspergilloma are higher in patients with tuberculous cavities than in those who are simply immunocompromised. [74] Postoperative complications almost exclusively affect symptomatic patients. [78] The most common surgical complications for complex aspergillomas [79] include bleeding, prolonged air leaks, bronchopleural fistula, and Aspergillus infection of the residual cavity. Poor preoperative general condition is a risk factor for complications. Comprehensive preoperative management is recommended, including treatment of malnutrition, cessation of alcohol and tobacco use, and stabilization of underlying conditions, particularly diabetes. Preoperative antifungal treatment is also recommended.

When pulmonary resection is deemed too risky due to the patient’s general condition or contraindicated by respiratory failure, a simple drainage of the abscessed cavity may be performed, [82] [78] followed, if necessary, by thoracoplasty, [83] which aims to collapse the residual cavity.

Other treatments

In cases of massive hemoptysis due to complex aspergilloma, bronchial artery embolization may be performed. [84] However, outcomes are less favorable compared to other causes of hemoptysis due to the hypervascularization of complex aspergillomas. [85] Embolization is considered a temporary measure pending surgery outside of life-threatening emergencies or antifungal treatment in cases of definitive surgical contraindication. [86]

Direct administration of antifungals into the aspergilloma cavity (most commonly amphotericin B [87] [88] ) yields variable results. [31] In 2009, it was primarily used to treat massive hemoptysis in inoperable patients, [31] and a 2013 study noted that its long-term benefits remain unknown. [88]

Considerations in Immunocompromised patients

In patients on immunosuppressive therapy, reducing the intensity of immunosuppression as much as possible is recommended upon suspicion of diagnosis to slow disease progression.

Prognosis and follow-up

Historically identified prognostic factors include the severity of underlying lung disease, [30] rapid radiological or biological worsening, [89] immunodeficiency, and coexisting sarcoidosis [90] or HIV infection. [32]

A good treatment response is defined by the regression of radiologically observed lesions. [42] The correlation between initial response quality and long-term prognosis has not been studied. [34] Approximately 50% of patients show clinical and radiological improvement within the first year. [34]

The goal of follow-up is to ensure the absence of progression of complex aspergilloma lesions. A control CT scan is recommended 3 to 6 months after treatment initiation. [15] [91] A low-dose CT scan, which is less irradiating, is recommended. [92] [93] Long-term surgical outcomes primarily depend on the patient’s general condition. [78]

Long-term mortality (over 10 years post-diagnosis) ranges from 37 to 67% across studies. [34] Risk factors for mortality include advanced age, corticosteroid therapy, low body weight (BMI < 18.5)), and inflammatory syndrome at diagnosis. [94] Lung tissue destruction and respiratory failure are also poor prognostic factors. [30] [34]

References

  1. ↑ Micheli, Pier Antonio (1729). Nova plantarum genera [New genera of plants] (in Latin). Florence. p. 212. Retrieved October 20, 2025.
  2. ↑ Bennett, John Hughes (January 1844). "XVII. On the Parasitic Vegetable Structures found growing in Living Animals". Transactions of the Royal Society of Edinburgh. 15 (2). Cambridge University Press: 277–294. doi:10.1017/s0080456800029963. ISSN   0080-4568 . Retrieved October 20, 2025.
  3. 1 2 Hinson, K. F. W.; Moon, A. J.; Plummer, N. S. (December 1952). "Broncho-pulmonary Aspergillosis: Review and a Report of Eight New Cases". Thorax. 7 (4). BMJ: 317–333. doi:10.1136/thx.7.4.317. PMC   1019200 . PMID   13015523.
  4. ↑ Sluyter, Theodor (1847). "De vegetabilibus organismi animalis parasitis, ac de novo epiphyto in pityriasi versicolore obvio" [On parasitic vegetable organisms of the animal body, and on a new epiphyte found in pityriasis versicolor]. Diss Inaug Berlin (in Latin). Berolini: 25.
  5. ↑ Küchenmeister, Friedrich (1855). Die in und an dem Körper des lebenden Menschen vorkommenden Parasiten [Parasites occurring in and on the body of living humans] (in German). Leipzig: B.G. Teubner . Retrieved October 20, 2025.
  6. ↑ Friedreich, N. (December 1856). "Fall von Pneumonomycosis aspergillina" [Case of Pneumonomycosis aspergillina]. Virchows Archiv (in German). 10 (4): 510–512. doi:10.1007/BF02116589. ISSN   0945-6317 . Retrieved October 20, 2025.
  7. ↑ Fürbringer, Paul (March 1876). "Beobachtungen über Lungenmycose beim Menschen" [Observations on pulmonary mycosis in humans]. Virchows Archiv (in German). 66 (3): 330–365. doi:10.1007/BF01878266. ISSN   0945-6317 . Retrieved October 20, 2025.
  8. ↑ Dévé, F. (1938). "Une nouvelle forme anatomo-radiologique de mycose pulmonaire primitive: le mégamycétome intra bronchiectatique" [A new anatomo-radiological form of primary pulmonary mycosis: the intrabronchiectatic megamycetoma]. Arch Med Chir Appar Resp (in French). 13: 337–361., cited by Denning et al.
  9. ↑ Kelmenson, Victor A. (October 1, 1959). "Treatment of Pulmonary Aspergillosis". Chest Journal. 36 (4). Elsevier BV: 442–443. doi:10.1378/chest.36.4.442. ISSN   0012-3692. PMID   14405328 . Retrieved October 20, 2025.
  10. ↑ Daly, R. C.; Pairolero, P. C.; Piehler, J. M.; Trastek, V. F.; Payne, W. S.; Bernatz, P. E. (December 1986). "Pulmonary aspergilloma. Results of surgical treatment". The Journal of Thoracic and Cardiovascular Surgery. 92 (6). Elsevier BV: 981–988. doi:10.1016/S0022-5223(19)35813-1. ISSN   0022-5223. PMID   3097424.
  11. 1 2 3 4 5 6 7 8 Latgé (1999)
  12. ↑ "Aspergillose" [Aspergillosis]. Institut Pasteur (in French). January 2013. Retrieved October 20, 2025.
  13. 1 2 3 4 5 6 7 Kosmidis & Denning (2014)
  14. 1 2 3 4 5 6 7 8 9 10 11 Passera et al. (2012)
  15. 1 2 3 4 Felton, Timothy W.; Baxter, Caroline; Moore, Caroline; Roberts, Stephen; Hope, William; Denning, David (December 15, 2010). "Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis". Clinical Infectious Diseases. 51 (12). Oxford University Press: 1383–1391. doi:10.1086/657306. ISSN   1058-4838. PMID   21054179 . Retrieved October 20, 2025.
  16. 1 2 Smith, N. L.; Denning, D. W. (July 1, 2010). "Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma". European Respiratory Journal. 37 (4). European Respiratory Society: 865–872. doi:10.1183/09031936.00054810. ISSN   0903-1936. PMID   20595150 . Retrieved October 20, 2025.
  17. 1 2 Bopaka, R. G.; El Khattabi, W.; Choubi, M.; El Bied, B.; Aichane, A.; Afif, H. (January 2015). "Aspergillomes pulmonaires" [Pulmonary aspergillomas]. Revue des Maladies Respiratoires (in French). 32. Elsevier BV: A159. doi:10.1016/j.rmr.2014.10.136. ISSN   0761-8425 . Retrieved October 20, 2025.
  18. 1 2 Denning, David; Pleuvry, Alex; Cole, Donald (December 1, 2011). "Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis". Bulletin of the World Health Organization. 89 (12). WHO Press: 864–872. doi:10.2471/blt.11.089441. ISSN   0042-9686. PMC   3260898 . PMID   22271943 . Retrieved October 20, 2025.
  19. ↑ Greenberg, Alissa K.; Knapp, Jocelyn; Rom, William N.; Addrizzo-Harris, Doreen J. (September 2002). "Clinical Presentation of Pulmonary Mycetoma in HIV-Infected Patients". Chest. 122 (3). Elsevier BV: 886–892. doi:10.1378/chest.122.3.886. ISSN   0012-3692. PMID   12226028 . Retrieved October 20, 2025.
  20. ↑ Hours, Sandrine; Nunes, Hilario; Kambouchner, Marianne; Uzunhan, Yurdagül; Brauner, Michel W.; Valeyre, Dominique; Brillet, Pierre-Yves (May 2008). "Pulmonary Cavitary Sarcoidosis". Medicine. 87 (3). Ovid Technologies (Wolters Kluwer Health): 142–151. doi:10.1097/md.0b013e3181775a73. ISSN   0025-7974 . Retrieved October 20, 2025.
  21. ↑ Denning, David W.; Pleuvry, Alex; Cole, Donald C. (June 27, 2012). "Global burden of chronic pulmonary aspergillosis complicating sarcoidosis". Eur Respir J. 41 (3). European Respiratory Society: 621–626. doi:10.1183/09031936.00226911. ISSN   0903-1936. PMID   22743676 . Retrieved October 20, 2025.
  22. 1 2 Tamura, Atsuhisa; Suzuki, Junko; Fukami, Takeshi; Matsui, Hirotoshi; Akagawa, Shinobu; Ohta, Ken; Hebisawa, Akira; Takahashi, Fumiaki (August 30, 2015). "Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer". Interact CardioVasc Thorac Surg. 21 (5). Oxford University Press: 650–656. doi:10.1093/icvts/ivv239. ISSN   1569-9293 . Retrieved October 20, 2025.
  23. 1 2 3 4 Dheda, Keertan; Booth, Helen; Huggett, Jim F.; Johnson, Margaret A.; Zumla, Alimuddin; Rook, Graham W. (October 2005). "Lung Remodeling in Pulmonary Tuberculosis". The Journal of Infectious Diseases. 192 (7). Oxford University Press: 1201–1209. doi:10.1086/444545. ISSN   0022-1899. PMID   16136463 . Retrieved October 20, 2025.
  24. 1 2 3 Ong, Catherine W. M.; Elkington, Paul T.; Friedland, Jon S. (July 2014). "Tuberculosis, Pulmonary Cavitation, and Matrix Metalloproteinases". Am J Respir Crit Care Med. 190 (1). American Thoracic Society: 9–18. doi:10.1164/rccm.201311-2106pp. ISSN   1073-449X. PMC   4226026 . PMID   24713029 . Retrieved October 20, 2025.
  25. 1 2 Saeed, Waseem (February 1, 2012). "Cavitating pulmonary tuberculosis: a global challenge". Clinical Medicine. 12 (1). Royal College of Physicians: 40–41. doi:10.7861/clinmedicine.12-1-40. ISSN   1470-2118 . Retrieved October 20, 2025.
  26. ↑ Rakotoson, Joelson Lovaniaina; Razafindramaro, Notahiana; Rakotomizao, Jocelyn Robert; Vololontiana, Hanta Marie Danielle; Andrianasolo, Radonirina Lazasoa; Ravahatra, Kiady; Tiaray, Michel; Rajaoarifetra, Jobeline; Rakotoharivelo, Hendriniaina; Andrianarisoa, Ange Christophe Félix (August 2011). "Les aspergillomes pulmonaires: à propos de 37 cas à Madagascar" [Pulmonary aspergillomas: a study of 37 cases in Madagascar]. The Pan African Medical Journal (in French). 10 (4). doi:10.11604/pamj.2011.10.4.936. ISSN   1937-8688 . Retrieved October 20, 2025.
  27. ↑ Massard, G. (June 2005). "Place de la chirurgie dans le traitement des aspergilloses thoraciques" [The role of surgery in the treatment of thoracic aspergillosis]. Revue des Maladies Respiratoires (in French). 22 (3). Elsevier-Masson: 466–472. doi:10.1016/S0761-8425(05)85574-3. PMID   16227932 . Retrieved October 20, 2025.
  28. 1 2 Howard, S. J.; Pasqualotto, A. C.; Anderson, M. J.; Leatherbarrow, H.; Albarrag, A. M.; Harrison, E.; Gregson, L.; Bowyer, P.; Denning, D. W. (February 1, 2013). "Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis". Mycoses. 56 (4). Wiley-Blackwell: 434–441. doi:10.1111/myc.12047. ISSN   0933-7407. PMID   23369025 . Retrieved October 20, 2025.
  29. ↑ Marcq, M.; Germaud, P.; Cellerin, L.; Sagan, C.; Chailleux, E. (December 2004). "Aspergilloses respiratoires complexes : difficultés diagnostiques et thérapeutiques" [Complex respiratory aspergillosis: diagnostic and therapeutic challenges]. Revue des Maladies Respiratoires (in French). 21 (6): 1162–1166. doi:10.1016/S0761-8425(04)71593-4. ISSN   0761-8425. PMID   15767963 . Retrieved October 20, 2025.
  30. 1 2 3 4 5 Stevens et al. (2000)
  31. 1 2 3 4 5 6 7 Riscili, Brent P.; Wood, Karen L. (June 2009). "Noninvasive Pulmonary Aspergillus Infections". Clinics in Chest Medicine. 30 (2). Elsevier BV: 315–335. doi:10.1016/j.ccm.2009.02.008. ISSN   0272-5231. PMID   19375638 . Retrieved October 20, 2025.
  32. 1 2 Addrizzo-Harris, Doreen J.; Harkin, Timothy J.; McGuinness, Georgeann; Naidich, David P.; Rom, William N. (March 1997). "Pulmonary Aspergilloma and AIDS". Chest. 111 (3). Elsevier BV: 612–618. doi:10.1378/chest.111.3.612. ISSN   0012-3692 . Retrieved October 20, 2025.
  33. 1 2 3 4 Svirshchevskaya, Elena; Zubkov, Dmitrii; Mouyna, Isabelle; Berkova, Nadia (May 1, 2012). "Innate Immunity and the Role of Epithelial Barrier During Aspergillus fumigatus Infection". Current Immunology Reviews. 8 (3). Bentham Science Publishers Ltd.: 254–261. doi:10.2174/157339512800671985. ISSN   1573-3955. PMC   3520052 . PMID   23255875 . Retrieved October 20, 2025.
  34. 1 2 3 4 5 6 7 8 Schweer, K. E.; Bangard, C.; Hekmat, K.; Cornely, O. A. (December 2, 2013). "Chronic pulmonary aspergillosis". Mycoses. 57 (5). Wiley-Blackwell: 257–270. doi:10.1111/myc.12152. ISSN   0933-7407. PMID   24299422 . Retrieved October 20, 2025.
  35. ↑ Kaur, Savneet; Singh, Shweta (August 21, 2013). "Biofilm formation by Aspergillus fumigatus". Med Mycol. Oxford University Press: 1–8. doi:10.3109/13693786.2013.819592. ISSN   1369-3786 . Retrieved October 20, 2025.
  36. ↑ Croft, Carys A.; Culibrk, Luka; Moore, Margo M.; Tebbutt, Scott J. (April 7, 2016). "Interactions of Aspergillus fumigatus Conidia with Airway Epithelial Cells: A Critical Review". Front. Microbiol. 7. Frontiers Media SA. doi:10.13039/501100000038. ISSN   1664-302X . Retrieved October 20, 2025.
  37. ↑ Monod, M.; Jaton-Ogay, K.; Reichard, U. (1999). "Aspergillus fumigatus-Secreted Proteases As Antigenic Molecules and Virulence Factors". Aspergillus Fumigatus. S. Karger AG: 182–192. doi:10.1159/000060294. ISBN   3-8055-6714-6 . Retrieved October 20, 2025.
  38. ↑ Smith, N. L. D.; Hankinson, J.; Simpson, A.; Bowyer, P.; Denning, D. W. (August 2014). "A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis". Clinical Microbiology and Infection. 20 (8). Elsevier BV: O480 –O488. doi:10.13039/501100000272. ISSN   1198-743X. PMID   24274595 . Retrieved October 20, 2025.
  39. ↑ Vaid, Mudit; Kaur, Savneet; Sambatakou, Helen; Madan, Taruna; Denning, David W.; Sarma, P. Usha (January 1, 2007). "Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis". Clinical Chemical Laboratory Medicine. 45 (2). Walter de Gruyter GmbH. doi:10.1515/cclm.2007.033. ISSN   1434-6621 . Retrieved October 20, 2025.
  40. 1 2 3 Mahboub, F.; Jabri, H.; Elkhattabi, W.; Moubachir, H.; Afif, H. (January 2016). "Sérologie aspergillaire et diagnostic des aspergillomes pulmonaires" [Aspergillar serology and diagnosis of pulmonary aspergillomas]. Revue des Maladies Respiratoires (in French). 33. Elsevier BV: A231 –A232. doi:10.1016/j.rmr.2015.10.506. ISSN   0761-8425 . Retrieved October 20, 2025.
  41. ↑ Shah, Rajeev; Vaideeswar, Pradeep; Pandit, Shobhana P. (2008). "Pathology of pulmonary aspergillomas". Indian Journal of Pathology and Microbiology. 51 (3). Medknow: 342. doi: 10.4103/0377-4929.42507 . ISSN   0377-4929. PMID   18723954.
  42. 1 2 Lee, Jung-Kyu; Lee, Yeon Joo; Park, Sung Soo; Park, Jong Sun; Cho, Young-Jae; Park, Young Sik; Yoon, Ho Il; Lee, Choon-Taek; Lee, Jae Ho (July 3, 2014). "Clinical course and prognostic factors of pulmonary aspergilloma". Respirology. 19 (7). Wiley-Blackwell: 1066–1072. doi:10.1111/resp.12344. ISSN   1323-7799. PMID   24995570 . Retrieved October 20, 2025.
  43. 1 2 Uffredi, M. L.; Mangiapan, G.; Cadranel, J.; Kac, G. (August 1, 2003). "Significance of Aspergillus fumigatus Isolation from Respiratory Specimens of Nongranulocytopenic Patients". European Journal of Clinical Microbiology & Infectious Diseases. 22 (8). Springer Science + Business Media: 457–462. doi:10.1007/s10096-003-0970-y. ISSN   0934-9723. PMID   12898283 . Retrieved October 20, 2025.
  44. 1 2 3 4 5 Schelenz, Silke; Barnes, Rosemary A.; Barton, Richard C.; Cleverley, Joanne R.; Lucas, Sebastian B.; Kibbler, Christopher C.; Denning, David W. (April 2015). "British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases". The Lancet Infectious Diseases. 15 (4). Elsevier BV: 461–474. doi:10.1016/s1473-3099(15)70006-x. ISSN   1473-3099 . Retrieved October 20, 2025.
  45. 1 2 "Aspergillus : diagnostic biologique" [Aspergillus: biological diagnosis]. MemoBio (in French). Retrieved October 20, 2025.
  46. ↑ Choi, Young Rak; An, Jin Young; Kim, Mi Kyeong; Han, Hye-Suk; Lee, Ki Hyeong; Kim, Si-Wook; Lee, Ki Man; Choe, Kang Hyeon (2013). "The diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle aspiration as an initial diagnostic tool". Korean J Intern Med. 28 (6). Korean Association of Internal Medicine: 660–667. doi:10.3904/kjim.2013.28.6.660. ISSN   1226-3303. PMC   3846991 . PMID   24307841 . Retrieved October 20, 2025.
  47. ↑ Kono, Yuta; Tsushima, Kenji; Yamaguchi, Koichi; Kurita, Nao; Soeda, Seiko; Fujiwara, Akahito; Sugiyama, Shinya; Togashi, Yuki; Kasagi, Satoshi; To, Yasuo; Setoguchi, Yasuhiro (July 2013). "The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis". Respiratory Medicine. 107 (7). Elsevier BV: 1094–1100. doi:10.1016/j.rmed.2013.04.007. ISSN   0954-6111 . Retrieved October 20, 2025.
  48. ↑ Baxter, C.G.; Denning, D.W.; Jones, A.M.; Todd, A.; Moore, C.B.; Richardson, M.D. (April 2013). "Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis". Clinical Microbiology and Infection. 19 (4). Elsevier BV: E197 –E204. doi:10.1111/1469-0691.12133. ISSN   1198-743X. PMID   23331929 . Retrieved October 20, 2025.
  49. 1 2 Mayr, A.; Lass-Flörl, C. (2011). "Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature". Eur J Med Res. 16 (4). Springer Nature: 153. doi: 10.1186/2047-783x-16-4-153 . ISSN   2047-783X. PMID   21486729.
  50. ↑ Denning, D. (September 1, 1997). "Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection". Journal of Antimicrobial Chemotherapy. 40 (3). Oxford University Press: 401–414. doi:10.1093/jac/40.3.401. ISSN   1460-2091. PMID   9338494 . Retrieved October 20, 2025.
  51. ↑ Verweij, Paul E.; Howard, Susan J.; Melchers, Willem J.G.; Denning, David W. (December 2009). "Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints". Drug Resistance Updates. 12 (6). Elsevier BV: 141–147. doi:10.1016/j.drup.2009.09.002. ISSN   1368-7646. PMID   19879181 . Retrieved October 20, 2025.
  52. 1 2 3 4 Howard, Susan J.; Cerar, Dasa; Anderson, Michael J.; Albarrag, Ahmed; Fisher, Matthew C.; Pasqualotto, Alessandro C.; Laverdiere, Michel; Arendrup, Maiken C.; Perlin, David S.; Denning, David W. (July 2009). "Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure". Emerg. Infect. Dis. 15 (7). Centers for Disease Control and Prevention: 1068–1076. doi:10.3201/eid1507.090043. ISSN   1080-6040. PMID   19624922 . Retrieved October 20, 2025.
  53. ↑ Snelders, Eveline; van der Lee, Henrich A. L.; Kuijpers, Judith; Rijs, Anthonius J. M. M.; Varga, János; Samson, Robert A.; Mellado, Emilia; Donders, A. Rogier T.; Melchers, Willem J. G.; Verweij, Paul E. (November 11, 2008). "Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism". PLOS Med. 5 (11). Public Library of Science: e219. doi: 10.1371/journal.pmed.0050219 . ISSN   1549-1676. PMC   2581623 . PMID   18998768.
  54. 1 2 Chowdhary, Anuradha; Sharma, Cheshta; Hagen, Ferry; Meis, Jacques F. (May 2014). "Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms". Future Microbiology. 9 (5). Future Medicine Ltd: 697–711. doi:10.2217/fmb.14.27. ISSN   1746-0913 . Retrieved October 20, 2025.
  55. ↑ Georgiadou, Sarah P.; Kontoyiannis, Dimitrios P. (December 2012). "The impact of azole resistance on aspergillosis guidelines". Annals of the New York Academy of Sciences. 1272 (1). Wiley-Blackwell: 15–22. Bibcode:2012NYASA1272...15G. doi:10.1111/j.1749-6632.2012.06795.x. ISSN   0077-8923. PMID   23231710 . Retrieved October 20, 2025.
  56. 1 2 Sharma, S.; Dubey, S. K.; Kumar, N.; Sundriyal, D. (September 13, 2013). "'Monod' and 'air crescent' sign in aspergilloma". Case Reports. 2013 (sep13 1). BMJ: bcr2013200936. doi:10.1136/bcr-2013-200936. ISSN   1757-790X. PMID   24038294 . Retrieved October 20, 2025.
  57. ↑ Patterson, Karen C.; Strek, Mary E. (November 2014). "Diagnosis and Treatment of Pulmonary Aspergillosis Syndromes". Chest. 146 (5). Elsevier BV: 1358–1368. doi:10.1378/chest.14-0917. ISSN   0012-3692. PMID   25367472 . Retrieved October 20, 2025.
  58. ↑ Wang, Lan-Fu; Chu, Hsi; Chen, Yuh-Min; Perng, Reury-Perng (April 2007). "Adenocarcinoma of the Lung Presenting as a Mycetoma With an Air Crescent Sign". Chest. 131 (4). Elsevier BV: 1239–1242. doi:10.1378/chest.06-1551. ISSN   0012-3692. PMID   17426235 . Retrieved October 20, 2025.
  59. ↑ Chatterjee, Kshitij; Colaco, Brendon; Colaco, Clinton; Hellman, Michael; Meena, Nikhil (2015). "Rasmussen's aneurysm: A forgotten scourge". Respiratory Medicine Case Reports. 16. Elsevier BV: 74–76. doi:10.1016/j.rmcr.2015.08.003. ISSN   2213-0071. PMID   26744661 . Retrieved October 20, 2025.
  60. ↑ Syed, Madiha; Irby, Jill (August 12, 2015). "Airway management of ruptured pulmonary artery "Rasmussen" aneurysm and massive hemoptysis". BMC Research Notes. 8 (1) 346. Springer Science + Business Media. doi: 10.1186/s13104-015-1313-7 . ISSN   1756-0500. PMC   4534049 . PMID   26264527.
  61. ↑ Baxter, Caroline G.; Bishop, Paul; Low, Su Enn; Baiden-Amissah, Kweku; Denning, David W. (April 2, 2011). "Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography". Thorax. 66 (7). BMJ: 638–640. doi:10.1136/thx.2010.155515. ISSN   0040-6376. PMID   21460371 . Retrieved October 20, 2025.
  62. ↑ Gazzoni, Fernando F.; Severo, Luiz Carlos; Marchiori, Edson; Irion, Klaus L.; Guimarães, Marcos D.; Godoy, Myrna C.; Sartori, Ana P. G.; Hochhegger, Bruno (October 22, 2013). "Fungal diseases mimicking primary lung cancer: radiologic-pathologic correlation". Mycoses. 57 (4). Wiley-Blackwell: 197–208. doi:10.1111/myc.12150. ISSN   0933-7407. PMID   24147761 . Retrieved October 20, 2025.
  63. ↑ Warris, Adilia (November 2014). "The biology of pulmonary aspergillus infections". Journal of Infection. 69. Elsevier BV: S36 –S41. doi:10.1016/j.jinf.2014.07.011. ISSN   0163-4453. PMID   25135079 . Retrieved October 20, 2025.
  64. 1 2 3 4 Agarwal, Ritesh; Vishwanath, Gella; Aggarwal, Ashutosh N.; Garg, Mandeep; Gupta, Dheeraj; Chakrabarti, Arunaloke (March 18, 2013). "Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature". Mycoses. 56 (5). Wiley-Blackwell: 559–570. doi:10.1111/myc.12075. ISSN   0933-7407. PMID   23496375 . Retrieved October 20, 2025.
  65. ↑ Cucchetto, G.; Cazzadori, A.; Conti, M.; Cascio, G. L.; Braggio, P.; Concia, E. (November 29, 2014). "Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series". Infection. 43 (3). Springer Science + Business Media: 277–286. doi:10.1007/s15010-014-0711-4. ISSN   0300-8126. PMID   25432571 . Retrieved October 20, 2025.
  66. ↑ Tucker, R. M.; Denning, D. W.; Hanson, L. H.; Rinaldi, M. G.; Graybill, J. R.; Sharkey, P. K.; Pappagianis, D.; Stevens, D. A. (January 1, 1992). "Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations". Clinical Infectious Diseases. 14 (1). Oxford University Press: 165–174. doi:10.1093/clinids/14.1.165. ISSN   1058-4838. PMID   1315160 . Retrieved October 20, 2025.
  67. 1 2 Camuset, Juliette; Nunes, Hilario; Dombret, Marie-Christine; Bergeron, Anne; Henno, Priscilla; Philippe, Bruno; Dauriat, Gaelle; Mangiapan, Gilles; Rabbat, Antoine; Cadranel, Jacques (May 2007). "Treatment of Chronic Pulmonary Aspergillosis by Voriconazole in Nonimmunocompromised Patients". Chest. 131 (5). Elsevier BV: 1435–1441. doi:10.1378/chest.06-2441. ISSN   0012-3692. PMID   17400661 . Retrieved October 20, 2025.
  68. ↑ Nam, Hae-Seong; Jeon, Kyeongman; Um, Sang-Won; Suh, Gee Young; Chung, Man Pyo; Kim, Hojoong; Kwon, O. Jung; Koh, Won-Jung (June 2010). "Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases". International Journal of Infectious Diseases. 14 (6). Elsevier BV: e479 –e482. doi:10.1016/j.ijid.2009.07.011. ISSN   1201-9712. PMID   19910234 . Retrieved October 20, 2025.
  69. ↑ Kohno, Shigeru; Izumikawa, Koichi; Ogawa, Kenji; Kurashima, Atsuyuki; Okimoto, Niro; Amitani, Ryoichi; Kakeya, Hiroshi; Niki, Yoshihito; Miyazaki, Yoshitsugu (November 2010). "Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan". Journal of Infection. 61 (5). Elsevier BV: 410–418. doi:10.1016/j.jinf.2010.08.005. hdl:10069/24110. ISSN   0163-4453. PMID   20797407 . Retrieved October 20, 2025.
  70. ↑ Keir, G. J.; Garfield, B.; Hansell, D. M.; Loebinger, M. R.; Wilson, R.; Renzoni, E. A.; Wells, A. U.; Maher, T. M. (September 12, 2013). "Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis". Thorax. 69 (3). BMJ: 287–288. doi:10.1136/thoraxjnl-2013-203988. ISSN   0040-6376. PMID   24029745 . Retrieved October 20, 2025.
  71. 1 2 3 Benhamed, Lotfi; Woelffle, Didier (March 18, 2014). "Adjuvant antifungal therapy after pulmonary surgery for aspergilloma: is it useful?". Interact CardioVasc Thorac Surg. 18 (6). Oxford University Press: 835–837. doi:10.1093/icvts/ivu069. ISSN   1569-9293. PMID   24643620 . Retrieved October 20, 2025.
  72. ↑ Sagan, Dariusz; Gozdziuk, Kazimierz (May 2010). "Surgery for Pulmonary Aspergilloma in Immunocompetent Patients: No Benefit From Adjuvant Antifungal Pharmacotherapy". The Annals of Thoracic Surgery. 89 (5). Elsevier BV: 1603–1610. doi:10.1016/j.athoracsur.2010.02.037. ISSN   0003-4975. PMID   20417786 . Retrieved October 20, 2025.
  73. ↑ Pagès, P.-B.; Grima, R.; Mordant, P.; Grand, B.; Badia, A.; Le Pimpec-Barthes, F.; Bernard, A.; Riquet, M. (December 2014). "Un traitement antifongique périopératoire influence-t-il la morbidité postopératoire et la survie à long terme après une résection pulmonaire pour aspergillome ?" [Does perioperative antifungal treatment influence postoperative morbidity and long-term survival after pulmonary resection for aspergilloma?]. Revue de Pneumologie Clinique (in French). 70 (6). Elsevier BV: 322–328. doi:10.1016/j.pneumo.2014.08.002. ISSN   0761-8417. PMID   25457220 . Retrieved October 20, 2025.
  74. 1 2 3 Al-Kattan, K.; Ashour, M.; Hajjar, W.; Salah El Din, M.; Fouda, M.; Al Bakry, A. (October 2001). "Surgery for pulmonary aspergilloma in post-tuberculous vs. immuno-compromised patients". European Journal of Cardio-Thoracic Surgery. 20 (4). Oxford University Press: 728–733. doi:10.1016/s1010-7940(01)00837-5. ISSN   1010-7940. PMID   11574215 . Retrieved October 20, 2025.
  75. 1 2 Massard, G. (June 2005). "Place de la chirurgie dans le traitement des aspergillomes" [The role of surgery in the treatment of aspergillomas]. Revue des Maladies Respiratoires (in French). 22 (3): 466–472. doi:10.1016/S0761-8425(05)85574-3. ISSN   0761-8425 . Retrieved May 17, 2016.
  76. 1 2 Caidi, Mohamed; Kabiri, Hassane; Al Aziz, Said; El Maslout, Abderrahman; Benosman, Abdellatif (December 2006). "Chirurgie des aspergillomes pulmonaires" [Surgery for pulmonary aspergillomas]. La Presse Médicale (in French). 35 (12). Elsevier BV: 1819–1824. doi:10.1016/s0755-4982(06)74907-7. ISSN   0755-4982. PMID   17159733 . Retrieved October 20, 2025.
  77. ↑ Shiraishi, Yuji; Katsuragi, Naoya; Nakajima, Yutsuki; Hashizume, Masahiro; Takahashi, Nobumasa; Miyasaka, Yoshikazu (January 2006). "Pneumonectomy for complex aspergilloma: is it still dangerous?". European Journal of Cardio-Thoracic Surgery. 29 (1). Oxford University Press: 9–13. doi:10.1016/j.ejcts.2005.10.043. ISSN   1010-7940 . Retrieved October 20, 2025.
  78. 1 2 3 4 Regnard, Jean-François; Icard, Philippe; Nicolosi, Maurizio; Spagiarri, Lorenzo; Magdeleinat, Pierre; Jauffret, Bertrand; Levasseur, Philippe (March 2000). "Aspergilloma: a series of 89 surgical cases". The Annals of Thoracic Surgery. 69 (3). Elsevier BV: 898–903. doi:10.1016/s0003-4975(99)01334-x. ISSN   0003-4975. PMID   10750780 . Retrieved October 20, 2025.
  79. 1 2 3 Farid, Shakil; Mohamed, Shaza; Devbhandari, Mohan; Kneale, Matthew; Richardson, Malcolm; Soon, Sing Y; Jones, Mark T; Krysiak, Piotr; Shah, Rajesh; Denning, David W; Rammohan, Kandadai (2013). "Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre's experience". J Cardiothorac Surg. 8 (1). Springer Nature: 180. doi: 10.1186/1749-8090-8-180 . ISSN   1749-8090.
  80. ↑ Brik, Alaa; Salem, Abdel Meged; Kamal, Al Rady; Abdel-Sadek, Mohamed; Essa, Mohamed; El Sharawy, Mamdoh; Deebes, Ahmed; Abdel Bary, Khaled (October 2008). "Surgical outcome of pulmonary aspergilloma". European Journal of Cardio-Thoracic Surgery. 34 (4). Oxford University Press: 882–885. doi:10.1016/j.ejcts.2008.06.049. ISSN   1010-7940. PMID   18701313 . Retrieved October 20, 2025.
  81. ↑ Rivera, Caroline; Arame, Alex; Pricopi, Ciprian; Riquet, Marc; Mangiameli, Giuseppe; Abdennadher, Mahdi; Dahan, Marcel; Le Pimpec Barthes, Françoise (November 20, 2014). "Pneumonectomy for benign disease: indications and postoperative outcomes, a nationwide study". Eur J Cardiothorac Surg. 48 (3). Oxford University Press: 435–440. doi:10.1093/ejcts/ezu439. ISSN   1010-7940 . Retrieved October 20, 2025.
  82. ↑ Nakada, Takeo; Akiba, Tadashi; Inagaki, Takuya; Morikawa, Toshiaki; Ohki, Takao (July 2014). "Simplified Cavernostomy Using Wound Protector for Complex Pulmonary Aspergilloma". The Annals of Thoracic Surgery. 98 (1). Elsevier BV: 360–361. doi:10.1016/j.athoracsur.2013.11.087. ISSN   0003-4975. PMID   24996732 . Retrieved October 20, 2025.
  83. ↑ Grima, Renaud; Krassas, Athanase; Bagan, Patrick; Badia, Alain; Le Pimpec Barthes, Françoise; Riquet, Marc (November 2009). "Treatment of complicated pulmonary aspergillomas with cavernostomy and muscle flap: interest of concomitant limited thoracoplasty". European Journal of Cardio-Thoracic Surgery. 36 (5). Oxford University Press: 910–913. doi:10.1016/j.ejcts.2009.05.007. ISSN   1010-7940. PMID   19595606 . Retrieved October 20, 2025.
  84. ↑ Kato, Akira; Kudo, Sho; Matsumoto, Koichi; Fukahori, Tetsuhiro; Shimizu, Toshihisa; Uchino, Akira; Hayashi, Shinichiro (July 15, 2000). "Bronchial Artery Embolization for Hemoptysis Due to Benign Diseases: Immediate and Long-Term Results". CardioVascular and Interventional Radiology. 23 (5). Springer Science + Business Media: 351–357. doi:10.1007/s002700010062. ISSN   0174-1551 . Retrieved October 20, 2025.
  85. ↑ Chen, Jie; Chen, Liang-an; Liang, Zhi-Xin; Li, Chun-Sun; Tian, Qing; Yang, Zhen; Jiang, Yan-Wen; She, Dan-Yang (September 2014). "Immediate and Long-term Results of Bronchial Artery Embolization for Hemoptysis Due to Benign Versus Malignant Pulmonary Diseases". The American Journal of the Medical Sciences. 348 (3). Elsevier BV: 204–209. doi:10.1097/maj.0000000000000226. ISSN   0002-9629. PMID   24556929 . Retrieved October 20, 2025.
  86. ↑ Corr, Peter (June 29, 2006). "Management of Severe Hemoptysis from Pulmonary Aspergilloma Using Endovascular Embolization". CardioVascular and Interventional Radiology. 29 (5). Springer Science + Business Media: 807–810. doi:10.1007/s00270-005-0329-0. ISSN   0174-1551 . Retrieved October 20, 2025.
  87. ↑ Takeda, Takayuki; Itano, Hideki; Kakehashi, Ryouhei; Fukita, Shinichi; Saitoh, Masahiko; Takeda, Sorou (2014). "Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma". Respiratory Medicine Case Reports. 11. Elsevier BV: 7–11. doi:10.1016/j.rmcr.2013.12.003. ISSN   2213-0071 . Retrieved October 20, 2025.
  88. 1 2 Kravitz, Jared N.; Berry, Max W.; Schabel, Stephen I.; Judson, Marc A. (May 2013). "A Modern Series of Percutaneous Intracavitary Instillation of Amphotericin B for the Treatment of Severe Hemoptysis From Pulmonary Aspergilloma". Chest. 143 (5). Elsevier BV: 1414–1421. doi:10.1378/chest.12-1784. ISSN   0012-3692. PMID   23117277 . Retrieved October 20, 2025.
  89. ↑ Tomee, J F; van der Werf, T S; Latge, J P; Koeter, G H; Dubois, A E; Kauffman, H F (January 1995). "Serologic monitoring of disease and treatment in a patient with pulmonary aspergilloma". Am J Respir Crit Care Med. 151 (1). American Thoracic Society: 199–204. doi:10.1164/ajrccm.151.1.7812553. ISSN   1073-449X . Retrieved October 20, 2025.
  90. ↑ Tomlinson, James R.; Sahn, Steven A. (September 1987). "Aspergilloma in Sarcoid and Tuberculosis". Chest. 92 (3). Elsevier BV: 505–508. doi:10.1378/chest.92.3.505. ISSN   0012-3692. PMID   3622028 . Retrieved October 20, 2025.
  91. ↑ Cadranel, J.; Philippe, B.; Hennequin, C.; Bergeron, A.; Bergot, E.; Bourdin, A.; Cottin, V.; Jeanfaivre, T.; Godet, C.; Pineau, M.; Germaud, P. (July 11, 2012). "Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial". Eur J Clin Microbiol Infect Dis. 31 (11). Springer Science + Business Media: 3231–3239. doi:10.1007/s10096-012-1690-y. ISSN   0934-9723. PMID   22782438 . Retrieved October 20, 2025.
  92. ↑ Lavaud, Stéphanie (July 5, 2011). "Le scanner « low dose », un espoir pour le dépistage du cancer du poumon" [The "low dose" CT scan, a hope for lung cancer screening]. Medscape (in French). Retrieved June 26, 2016.
  93. ↑ Hendee, William R.; Edwards, F. Marc (April 1986). "ALARA and an integrated approach to radiation protection". Seminars in Nuclear Medicine. 16 (2). Elsevier BV: 142–150. doi:10.1016/s0001-2998(86)80027-7. ISSN   0001-2998. PMID   3961515 . Retrieved October 20, 2025.
  94. ↑ Nakamoto, Keitaro; Takayanagi, Noboru; Kanauchi, Tetsu; Ishiguro, Takashi; Yanagisawa, Tsutomu; Sugita, Yutaka (2013). "Prognostic Factors in 194 Patients with Chronic Necrotizing Pulmonary Aspergillosis". Intern. Med. 52 (7). Japanese Society of Internal Medicine: 727–734. doi:10.2169/internalmedicine.52.9142. ISSN   0918-2918. PMID   23545666 . Retrieved October 20, 2025.

Bibliography

General articles

Professional Society guidelines

See also

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.